- Home
- SEPN
SEPN
SEPTERNA INC
as 02-21-2025 4:00pm EST
Stocks
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.
Upcoming Earnings Alert:
Get ready for potential market movements as SEPTERNA INC SEPN prepares to release earnings report on 28 Feb 2025.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 631.0M | IPO Year: | 2024 |
| Target Price: | $34.00 | AVG Volume (30 days): | 837.7K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.17 - $28.99 | Next Earning Date: | 02-28-2025 |
| Revenue: | $981,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 406.62% | Revenue Growth (next year): | -53.33% |
Latest SEPTERNA INC News
SEPN Breaking Stock News: Dive into SEPN Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Top Midday Decliners
MT Newswires
4 days ago
Septerna Discontinues Phase 1 Trial of SEP-786 for Hypoparathyroidism; Shares Fall Pre-Bell
GlobeNewswire
4 days ago
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
BioPharma Dive
8 days ago
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public
Insider Monkey
16 days ago
Septerna, Inc. (SEPN): Among the Best Rebound Stocks to Invest In Now
GlobeNewswire
2 months ago
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
GlobeNewswire
2 months ago
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TipRanks
3 months ago
Septerna, Inc. Reports Q3 2024 Financials and Progress
Compare SEPN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SEPN SEPTERNA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.